As summer calls us outdoors, a crucial health warning emerges from medical experts. While Lyme disease often grabs headlines, ...

RESVIA is now authorized for use in adults aged 18–59 years with an increased risk of respiratory syncytial virus-related ...

To address this, a French multi-centre prospective pregnancy observational cohort was set up, to analyse disease activity, treatment, pregnancy ...

(NASDAQ:MRNA) today announced that the U.S. Food and Drug Administration (FDA) has approved mRESVIA® (mRNA-1345), the Company’s respiratory syncytial virus (RSV) vaccine, for the prevention of lower ...

FDA drug alerts in infectious diseases, including new drug approvals, safety warnings, recalls, and changes in indications.